Jefferies analyst Michael Yee has maintained their bullish stance on BPMC stock, giving a Buy rating today.
Michael Yee’s rating is based on several strategic factors that position Blueprint Medicines favorably in the current market. The company is a commercial-stage biotech with minimal exposure to FDA risks and tariffs, which makes it a defensive choice in a volatile macroeconomic environment. Additionally, Blueprint Medicines has a strong balance sheet with low cash burn and the potential to reach profitability soon, reducing the need for additional equity raises.
Michael Yee also highlights the recent pullback in the stock as a buying opportunity, especially given the anticipated macroeconomic stability. He believes that the company’s focus on its SM franchise, particularly with the development of elenestinib, could expand its market potential. Despite a softer Q1 outlook due to seasonality factors, Yee expects the stock to perform well, especially if competitor data released in the summer does not surpass expectations. Overall, Blueprint Medicines is seen as a prime M&A target with a promising revenue trajectory.
According to TipRanks, Yee is an analyst with an average return of -4.0% and a 39.43% success rate. Yee covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Amgen, and Vertex Pharmaceuticals.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $128.00 price target.